Published in JAMA · View the paper (DOI)
A recent study found that prescriptions for direct-acting antivirals (DAAs) for hepatitis C increased rapidly after their introduction but declined sharply over time. As a result, many curable patients remain untreated, with treatment levels below national elimination targets.
Coverage from 2 institutions